Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com to Unlock Their Full Potential

Boehringer IngelheimBoehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.

"Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas," said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. "This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compounds with scientists around the world, we will advance scientific research and expect to spark discoveries that will lead to safe and effective new medicines for patients."

The molecules on opnMe.com are divided in two groups, offered under different conditions:

  • The majority of molecules are offered without entering into intellectual property discussions via a simple shopping cart system.
  • For selected molecules a crowdsourcing option offers the opportunity to initiate joint research projects. Scientists interested in such molecules for collaboration are invited to submit a research proposal. If the proposal is selected, the science will be developed together with Boehringer Ingelheim scientists.

This launch is part of Boehringer Ingelheim’s ongoing mission to further scientific research and medical progress through collaboration and innovation. Other initiatives include Research Beyond Borders and the Boehringer Ingelheim Venture Fund. They are part of the company's long-standing and continuing work in core therapeutic areas of Cardiometabolic Diseases, Respiratory Diseases, Oncology, CNS Diseases and Immunology.

Clive Wood adds, "I invite interested scientists worldwide to visit opnMe.com to access our molecules. We will measure the success of this initiative in terms of new experiments, publications and relationships forged. This approach to open innovation reflects our determination to break down barriers to the advancement of biomedical research and bring breakthrough medicines to patients."

For further information, please visit:
https://opnme.com

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

Most Popular Now

Researchers Apply Computing Power to Tra…

Princeton researchers have developed a new computational method that increases the ability to track the spread of cancer cells from one part of the body to another. This migration of...

Philips Powers First Tele-Intensive Care…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Japan-based Showa University announced the launch of Japan's first telemedicine intensive care (eICU) program at Showa University...

Open Call SC1-DTH-10-2019-2020: Digital …

Digital solutions supporting a continuum of care across a range of health and care services can relieve the pressure on governments to provide more cost-effective health and care systems by...

AI and Radar Technologies could Help Dia…

People with diabetes could be able to monitor their blood sugar without drawing blood using a system now being developed at the University of Waterloo. In a recent study, researchers...

Bad Habits that Lead to Cancer, Chronic …

Does this sound like someone you know? He or she spends too much time in front of screens, gets little exercise and eats a diet high in fat and low...

Private Healthcare Data to be Captured b…

An initiative has been launched to ensure private healthcare data is recorded in the same way as NHS data in England, with the aim of improving consistency across the system...

Research Finds Three Major Failings in s…

In the scramble to bring successful apps for the diagnosis of skin cancer to market there is a concern that a lack of testing is risking public safety, according to...

New Tissue-Imaging Technology could Enab…

A new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes, report researchers at the University of Illinois. The system uses...

New Technology Helps to Improve Treatmen…

A new web-based "feedback" technology which allows therapists to accurately monitor how patients with depression are coping has been found to reduce the probability of deterioration during psychological treatment by...

Rapid Zika Detection Test Uses Smartphon…

The Zika virus, which continues to cause microcephaly and other neurological complications in infants whose mothers were infected during pregnancy, remains a public health concern. Investigators from Brigham and Women's...

AAL Market and Investment Report

The AAL Market and Investment Report was commissioned by the Ambient Assisted Living Association and aims to provide a consolidated view of the existing market and investment information in Europe...